Continuous glucose monitoring
In Scotland, CGM is available for all people with T1DM, and for all women with insulin-treated T2DM in pregnancy.
Ensure that all women with T1DM have access to CGM during pregnancy.
Consider CGM in pregnant women with T2DM.
There are instances where women with GDM and clinical teams may jointly consider use of CGM, for example in those who are unable to undertake home blood glucose monitoring, or where remote monitoring would be advantageous. Compared with T1DM and T2DM there is a smaller body of evidence examining the use of CGM in GDM, and the majority of studies do not differentiate between the type of CGM, nor between those who manage glucose levels with insulin, metformin or diet. Furthermore, while the evidence is mixed, most studies do not report benefits in perinatal outcomes associated with CGM use in women with GDM. There is therefore insufficient evidence to support a recommendation for the routine use of CGM in women with GDM.
Glycated haemoglobin (haemoglobin A1c)
For women with pre-existing diabetes (T1DM or T2DM), HbA1c should be measured at booking as this will help to predict risk of congenital anomalies, large for gestational age (LGA) infants and macrosomia.
Monitoring change in HbA1c between the first and third trimester should be considered in those with pre-existing diabetes.
Measurement of HbA1c in women with risk factors for GDM may be used to exclude pre-existing T2DM. This can predict women at highest risk of GDM later in pregnancy but is not a diagnostic test for GDM.
Use continuous glucose monitoring metrics, such as time in range (TIR) or Glucose Management Indicator (GMI) to assess glucose levels during pregnancy.